On Tuesday, Shares of Alibaba Group Holding Ltd (NYSE:BABA), gained 0.51% to $78.37.
Alibaba Group, declared the appointment of Michael Evans as President of Alibaba Group, effective right away.
Mr. Evans will continue his service as a administration member of the Alibaba Group Board, having formerly served as an independent director since the company’s initial public offering in September 2014.
Mr. Evans’ appointment highlights Alibaba Group’s strong commitment to globalizing its business. The company has made growing its business outside of China a top priority, and is also committed to significantly increasing cross-border trade between China and key markets.
Alibaba Group Holding Limited, through its auxiliaries, operates as an online and mobile commerce company in the People’s Republic of China and internationally. It operates Taobao Marketplace, an online shopping destination; Tmall, a third-party platform for brands and retailers; Juhuasuan, a group buying marketplace; Alibaba.com, an online wholesale marketplace; Alitrip, an online travel booking platform; 1688.com, an online wholesale marketplace; and AliExpress, a consumer marketplace.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), inclined 0.21% to $ 70.24, during its last trading session.
Teva Pharmaceutical Industries Ltd. and privately-held Immuneering Corporation, declared that the companies have reached a contract in which Teva will purchase a 51% equity share of the genomic-analysis company. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for improved discovery, development and clinical success.
Teva and Immuneering have worked together over the past several years to unlock noteworthy findings into genetic biomarkers, therapy-specific gene expression signatures, and breakthrough work in characterizing non-biological complex drugs (NBCDs). Teva’s majority holding in Immuneering provides right of first refusal in projects regarding the Company’s stated objective of developing, personalizing and improving treatment of disorders of the Central Nervous System (CNS).
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines.
Finally, MRC Global Inc (NYSE:MRC), ended its last trade with 13.67% gained, and closed at $13.67.
MRC Global Inc, declared second quarter 2015 results.
The company’s sales were $1.198 billion for the second quarter of 2015, which were 20% lower than the second quarter of 2014 and 7.3% lower than the first quarter of 2015. The decline was driven primarily by reduced activity in the upstream sector. Sales were also negatively influenced by the strengthening of the U.S. dollar, which reduced stated sales by $40.8 million. Net income accessible to common stockholders, which is net income less dividends attributable to preferred stockholders, for the second quarter of 2015, was $15.0 million, or $0.15 per diluted share, contrast to $39.3 million, or $0.38 per diluted share for the second quarter of 2014. Adjusted net income accessible to common stockholders, adjusted for certain severance, restructuring and finance charges for the second quarter of 2015, was $23.0 million, or $0.22 per diluted share, contrast to $42.9 million, or $0.42 per diluted share for the second quarter of 2014. Please refer to the reconciliation of adjusted net income accessible to common stockholders (a non‑GAAP measure) to net income accessible to common stockholders (a GAAP measure) in this release.
MRC Global Inc., through its auxiliaries, distributes pipes, valves, fittings, and related products and services to the energy and industrial sectors in the Unites States, Canada, and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
